Albers Jeffrey W. 4
4 · Kymera Therapeutics, Inc. · Filed Oct 14, 2025
Insider Transaction Report
Form 4
Albers Jeffrey W.
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-10-13−5,000→ 0 totalExercise: $10.34Exp: 2030-09-03→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-10-13$59.19/sh−5,000$295,949→ 0 total - Exercise/Conversion
Common Stock
2025-10-13$10.34/sh+5,000$51,700→ 5,000 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares underlying this stock option are fully vested and exercisable.